Fujifilm Launches Bio CDMO Division

Fujifilm Corporation has launched the Bio CDMO Division to expand its contract development and manufacturing operations for biopharmaceuticals, in response to strong market growth expectations. The ratio of biopharmaceuticals in the pharmaceutical market is rising, and is expected to continue expanding.

As biopharmaceuticals manufacturing requires the advanced technologies and facilities for culturing, separation and purification of proteins, there is growing demand that pharmaceutical companies outsource process development and manufacturing of biopharmaceuticals to CDMOs that the proper technological capabilities and advanced facilities. The contract development and manufacturing market is projected to achieve growth of 8% per annum accordingly.

Fujifilm conducts its contract development and manufacturing business for biopharmaceuticals, primarily at Fujifilm Diosynth Biotechnologies U.S.A., Inc. and Fujifilm Diosynth Biotechnologies UK Limited. They utilize advanced biotechnology using mammalian cells and microbes to efficiently produce proteins for use in biopharmaceuticals, and expert know-how in managing processes from culturing to separation and purification.

In 2014, the company acquired Kalon Biotherapeutics—today’s Fujifilm Diosynth Biotechnologies Texas, LLC—whose strength lies in vaccine manufacturing and high-potency low-volume manufacturing, to expand its business.

In this business field, Fujifilm has also developed the Apollo technology, which increases protein production volume by five times, and achieves 20% improvement in culturing efficiency, using its technologies to manufacture under constant conditions and superior quality control, developed in the photographic film business. Furthermore, it has made significant capital investments to reinforce the company’s capabilities, thereby achieving a high level of business growth. In this latest move, Fujifilm is separating its contract development and manufacturing operations for biopharmaceuticals from the Pharmaceutical Products Division to form the Bio CDMO Division. The company is setting up the standalone business division to further accelerate its decision-making process and enable more timely injection of management resources, with the aim of accelerating business growth. The division will also deal with the contract development and manufacturing of small-molecule pharmaceuticals to address broader needs of pharmaceutical companies. The company is targeting to bring the division’s revenue to 100 billion yen by FY2024/March.